Regulus floats after slashing IPO price but partner placements add to tally
This article was originally published in Scrip
Executive Summary
Regulus Therapeutics sold 11.25 million shares of common stock at $4 per share on 4 October - one-third of its earlier expectation of $10 to $12 per share - when its initial public offering debuted on the Nasdaq, but the company raised $70 million in total thanks to a concurrent private placement of 6.25 million shares with its partner AstraZeneca.
You may also be interested in...
IPO Outlook: 2021 Saw Record Numbers But Poor Returns; 2022 Looks Muted
Initial public offering momentum decelerated as stock prices declined last year, but even with lower valuations making M&A more attractive, the IPO market this year is expected to be active.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.